Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9FZYT)

Drug Name
Spesolimab Drug Info
Synonyms BI-655130
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Approved [1]
Palmoplantar pustulosis EA90.42 Phase 2 [2]
Plaque psoriasis EA90.0 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM9FZYT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting IL-1 receptor-like 2 (IL1RL2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nemvaleukin alfa DMOAZHY Ovarian cancer 2C73 Phase 3 [3]
Imsidolimab DMC3FOW Generalized pustular psoriasis EA90.40 Phase 3 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
IL-1 receptor-like 2 (IL1RL2) TTUS18T ILRL2_HUMAN Antagonist [2]

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761244.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913.
4 Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023 Jul 17;189(2):161-169.